Cancer nanomedicine: Is targeting our target?
Nanomedicine may have a delivery problem. Rigorous, realistic and holistic rethinking is needed to improve nanomedicine performance and increase patient benefit.
Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, Germany; Department of Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Twan
T
Lammers
Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, Germany.
Fabian
F
Kiessling
Pharmaceutical Science, Innovative Medicines, AstraZeneca, Macclesfield, SK10 2NA, UK.
Marianne
M
Ashford
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Wim
W
Hennink
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Daan
D
Crommelin
Department of Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Gert
G
Storm
Clin Cancer Res. 2012 Sep 15;18(18):4889-94
22829203
Adv Drug Deliv Rev. 2013 Jan;65(1):80-8
23036224
Sci Transl Med. 2015 Nov 18;7(314):314fs47
26582895
ACS Cent Sci. 2016 Jul 27;2(7):434-7
27504489